Anthera Pharmaceutic (ANTH) 3.03 $ANTH Biotechnology

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Anthera Pharmaceutic (ANTH) 3.03 $ANTH

Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Wed Jun 22, 7:20AM CDT
On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad based as five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by accessing their free trade alerts at:
TRVN: 5.95 (-0.14), PTLA: 23.84 (+0.03), ANTH: 3.03 (-0.05), NERV: 10.77 (+0.15)

Can the Rally in Anthera (ANTH) Shares Continue?
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:54AM CDT
Anthera Pharmaceuticals, Inc. (ANTH) has been on the move lately as the stock has risen by 22.1% in the past four weeks, and it is currently trading well above its 20-Day SMA
ANTH: 3.03 (-0.05)

How are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular Therapies
PR Newswire - Thu May 19, 7:35AM CDT
There is no saying when exactly the Biotech space will fully recover given the relentless pressures in pricing and lack in consumer confidence. One thing is for sure in the investors circle though - numerous opportunities are up for grabs but this industry requires due-diligence. Ahead of today's session, ActiveWallSt.com's presents four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Intra-Cellular Therapies Inc. (NASDAQ: ITCI). Receive your complimentary alerts on these stocks by signing up today at:
PTLA: 23.84 (+0.03), ANTH: 3.03 (-0.05), VTAE: 10.39 (+0.03), ITCI: 35.91 (-0.70)

CymaBay Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 3:05PM CDT
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today provided recent corporate highlights and announced financial results for the quarter ended March 31, 2016.
ANTH: 3.03 (-0.05), CBAY: 1.72 (+0.03)

Anthera reports 1Q loss
Automated Insights - Mon May 09, 7:47AM CDT
HAYWARD, Calif. (AP) _ Anthera Pharmaceuticals Inc. (ANTH) on Monday reported a loss of $11.7 million in its first quarter.
ANTH: 3.03 (-0.05)

Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quarter Financial Results
GlobeNewswire - Mon May 09, 7:38AM CDT
-- SOLUTION clinical study of Sollpura(TM) expanded to Europe, Israel and Canada in addition to ongoing US enrollment
ANTH: 3.03 (-0.05)

Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors
GlobeNewswire - Wed Apr 27, 3:06PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of Brent Furse to its Board of Directors.
ANTH: 3.03 (-0.05)

Greenphire Empowers Orphan Drug and Rare Disease Clinical Research
PR Newswire - Tue Apr 19, 7:07AM CDT
Greenphire, the global leader in clinical payment solutions, today announced that its ClinCard Travel Module solution continues to empower clinical research in the orphan drug and rare disease market. With this announcement, Greenphire has expanded its client partners to include Anthera Pharmaceuticals, a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs.
ANTH: 3.03 (-0.05)

CymaBay Reports Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Tue Mar 29, 3:05PM CDT
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today provided recent corporate highlights and announced financial results for the quarter and year ended December 31, 2015.
ANTH: 3.03 (-0.05), CBAY: 1.72 (+0.03)

Anthera Pharmaceuticals Provides Business Update and Reports 2015 Fourth Quarter and Fiscal Year Financial Results
GlobeNewswire - Thu Mar 10, 7:37AM CST
-- SOLUTION clinical study of oral Sollpura(TM) enrollment to begin soon in Europe
ANTH: 3.03 (-0.05)

Anthera Pharmaceuticals Announces Appointment of Dr. James Pennington as Interim Chief Medical Officer
GlobeNewswire - Mon Mar 07, 7:37AM CST
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of James Pennington, M.D. as interim Chief Medical Officer following the Company's acceptance of Colin Hislop's resignation effective April 1, 2016.
ANTH: 3.03 (-0.05)

Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.40 (-0.08), DRNA: 3.17 (-0.04), INCY: 78.50 (+0.90), LLY: 73.07 (+0.50), STML: 6.92 (-0.14), SNTA: 0.31 (unch), ANTH: 3.03 (-0.05), EXEL: 7.74 (+0.07)

Nephropathy Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/hq5b5l/nephropathy) has announced the addition of the "Nephropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Nephropathy Overview - Therapeutics Development - Pipeline Products for Nephropathy - Overview - Pipeline Products for Nephropathy - Comparative Analysis - Nephropathy - Therapeutics under Development by Companies - Nephropathy - Therapeutics under Investigation by Universities/Institutes - Nephropathy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Nephropathy - Products under Development by Companies - Nephropathy - Products under Investigation by Universities/Institutes - Nephropathy - Companies Involved in Therapeutics Development - Anthera Pharmaceuticals Inc. - Boehringer Ingelheim GmbH - ChemoCentryx, Inc. - Complexa, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/hq...ephropathy
ANTH: 3.03 (-0.05), CCXI: 4.43 (-0.05)

Anthera Pharmaceuticals Announces Appointment of Craig Thompson as President and Chief Operating Officer and Dr. Chuck Olson as Chief Technology Officer
GlobeNewswire - Tue Jan 05, 4:30PM CST
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the appointment of Craig Thompson as President and Chief Operating Officer. In this role Mr. Thompson will oversee both of Anthera's late stage development programs and commercial preparation efforts. Anthera also announced the appointment of Chuck Olson, D.Sc. to the position of Chief Technology Officer replacing Debra Odink, Ph.D. who will continue to support the company in a key advisory role.
ANTH: 3.03 (-0.05)

Anthera Pharmaceuticals Announces Presentation at Healthcare Conferences, ACR Reception and Timing of Third Quarter Financial Results
GlobeNewswire - Wed Oct 28, 2:03PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the Company's attendance at the following healthcare conferences:
ANTH: 3.03 (-0.05)

Global Exocrine Pancreatic Insufficiency Pipeline Review, H2 2015 - 5 Companies & 5 Drug Profiles
M2 - Fri Oct 23, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mjv77n/exocrine) has announced the addition of the "Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Exocrine Pancreatic Insufficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Exocrine Pancreatic Insufficiency and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Anthera Pharmaceuticals Inc. - Cilian AG - Laboratoires Mayoly Spindler S.A.S. - Nordmark Arzneimittel GmbH & Co. KG Drug Profiles - burlulipase - Cilase - liprotamase - MS-1819 - pancrelipase DR For more information visit http://www.researchandmarkets.com/research/mjv77n/exocrine
AGN: 228.55 (-3.00), ANTH: 3.03 (-0.05)

Spark Therapeutics (ONCE) Slumps: Falls 11.1% in Session
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 7:45AM CDT
Spark Therapeutics' shares fell by over 11% on pretty good volume in the last session
ONCE: 46.65 (+0.09), ANTH: 3.03 (-0.05)

Global Systemic Lupus Erythematosus Pipeline Review, H2 2015 - 54 Companies & 84 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4734s/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Karyopharm Therapeutics, Inc. - Kineta, Inc. - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation For more information visit http://www.researchandmarkets.com/research/m4...emic_lupus
MGNX: 24.39 (+0.10), IMMU: 2.40 (-0.08), AMGN: 149.81 (+0.39), GSK: 41.76 (+0.11), BMY: 72.31 (+1.06), JNJ: 116.46 (+0.28), ARGS: 5.46 (-0.14), ANTH: 3.03 (-0.05), ABBV: 60.39 (+0.41), CBMG: 12.75 (-1.55), KPTI: 7.68 (+0.06), CELGZ: 1.45 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 744

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 91

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 278

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 102

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 66

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 94

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 407

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 473

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 118

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading

Top 5 Most Recently Viewed Articles

Sakai Seikotsuin's Role at Taipei Wake Open: A Glance Ahead

Updated Category News Views 219

Sakai Seikotsuin's Significant Contribution to the Taipei Wake Open In an exciting development for the athletic community, Sakai Seikotsuin Nishi Co., Ltd., a subsidiary of rYojbaba Co., Ltd. (NASDAQ: RYOJ), has been officially recognized as a key provider of trainer and medical support services at the prestigious Taipei Wake Open. This year marks the 10th anniversary of...

Continue Reading
Unlocking Economic Potential: The Case for English Workers in Québec

Updated Category News Views 187

Unlocking Economic Potential Through English-Speaking Workforce In an insightful report released recently, there is a compelling argument that addressing the employment and income disparities between English-speaking and French-speaking individuals in Québec could yield impressive financial benefits, potentially boosting the province's economy by $1.5 billion every year....

Continue Reading
Enhancing Healthcare Access with Innovative Technology Solutions

Updated Category News Views 183

Elevate Health Technologies Partners with D2 Solutions Elevate Health Technologies is proud to announce a significant partnership with D2 Solutions aimed at streamlining patient access to healthcare services. This collaboration focuses on advanced technology for prior authorizations, ensuring that patients receive timely access to essential medical care, which is crucial...

Continue Reading
Explore the Exciting New Wave of No Deposit Casinos Online

Updated Category News Views 239

The Rise of New Online Casinos with No Deposit Bonuses New online casinos in the US are transforming the gaming landscape, particularly through no deposit bonuses. These promotions allow players to try out gaming platforms without the financial risk of an initial deposit. More players are searching for genuine opportunities to explore online casinos that have just entered...

Continue Reading
Intergroup Corporation's Struggles: Navigating Market Challenges

Updated Category News Views 37

Intergroup Corporation Faces Market Pressures The Intergroup Corporation (INTG) finds itself in a tough market landscape, marked by a recent drop to a 52-week low, reaching $13.9 USD. This decline underscores a significant challenge, as the company has experienced a staggering 51.55% drop in stock value over the past year. Investors are keenly observing how Intergroup...

Continue Reading